Institutional members access full text with Ovid®

Share this article on:

A meta-analysis on alcohol drinking and the risk of Hodgkin lymphoma

Tramacere, Irenea; Pelucchi, Claudioa; Bonifazi, Martinaa; Bagnardi, Vincenzob,c; Rota, Matteob,e; Bellocco, Rinob,f; Scotti, Lorenzab; Islami, Farhadg,i,j; Corrao, Giovannib; Boffetta, Paoloh,j; La Vecchia, Carloa,d; Negri, Evaa

European Journal of Cancer Prevention: May 2012 - Volume 21 - Issue 3 - p 268–273
doi: 10.1097/CEJ.0b013e328350b11b
Review Article: Hematological cancer

The role of alcohol intake in the risk of Hodgkin lymphoma (HL) is still largely unclear. To summarize the evidence on the issue, we carried out a meta-analysis of the available studies. We identified eight case–control and two cohort studies, including a total of 1488 cases of HL. We derived meta-analytic estimates using random-effects models, taking into account the correlation between estimates, and carried out a dose–risk analysis using nonlinear random-effects metaregression models. Compared with nondrinkers, the relative risk for alcohol consumers was 0.70 [95% confidence interval (CI), 0.60–0.81] overall, 0.66 (95% CI, 0.56–0.78) among case–control, and 0.92 (95% CI, 0.63–1.33) among cohort studies. Compared with nondrinkers, the pooled relative risks were 0.71 (95% CI, 0.57–0.89) for light (i.e. ≤1 drink/day) and 0.73 (95% CI, 0.60–0.87) for moderate-to-heavy (i.e. >1 drink/day) alcohol drinking. This meta-analysis suggests a favourable effect of alcohol on HL, in the absence, however, of a dose–risk relationship. The inverse association was restricted to – or greater in – case–control as compared with cohort studies. This indicates caution in the interpretation of results.

aMario Negri Institute for Pharmacological Research

bDepartment of Statistics, University of Milano-Bicocca

cDivision of Epidemiology and Biostatistics, European Institute of Oncology

dDepartment of Occupational Health, University of Milano, Milan

eDepartment of Clinical Medicine and Prevention, Centre of Biostatistics for Clinical Epidemiology, University of Milano-Bicocca, Monza, Italy

fDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

gInternational Agency for Research on Cancer

hInternational Prevention Research Institute, Lyon, France

iDigestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

jThe Tisch Cancer Institute, Mount Sinai School of Medicine, New York, USA

Correspondence to Dr Claudio Pelucchi, ScD, Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156, Milan, Italy Tel: +39 02 39 01 4577; fax: +39 02 33 200 231; e-mail:

Received December 20, 2011

Accepted December 21, 2011

© 2012 Lippincott Williams & Wilkins, Inc.